PATENT CLAIM ANALYSIS

Application Number: 15779435
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "235800"]

Abstract:
The present invention relates to a novel imidazole compound or a pharmaceutically acceptable salt thereof having a melanocortin receptor agonistic activity, and medical use thereof. The present invention relates to an imidazole compound represented by general formula [I] [wherein: Ring A represents an optionally substituted aryl group or the like; R 1  represents a hydrogen atom, an optionally substituted alkyl group, or the like; R 2  represents a hydrogen atom, a halogen atom, or the like; and R 3  represents an optionally substituted alkyl group] or a pharmaceutically acceptable salt thereof.

Claim (Index 7):
The compound according to  claim 6 , wherein\n Ring A represents (1) a phenyl group optionally substituted with 1 to 2 groups independently selected from the group consisting of a halogen atom and an alkoxy group, or (2) a pyridyl group optionally substituted with 1 to 2 groups independently selected from the group consisting of a halogen atom;\n R 1  represents \n (1) an alkyl group optionally substituted with 1 to 2 groups independently selected from the group consisting of a halogen atom; a hydroxy group; a cyano group; an alkoxy group optionally substituted with a phenyl group; a phenyl group optionally substituted with a group selected from the group consisting of an alkylsulfonyl group and an aminosulfonyl group; a heteroaryl group optionally substituted with 1 to 2 groups independently selected from the group consisting of an oxo group and a hydroxy group, wherein said heteroaryl is selected from oxazolyl, oxadiazolyl, triazolyl, and pyridyl; a tetrahydroisoquinolyl group; an aliphatic heterocyclic group optionally substituted with 1 to 2 oxo groups, wherein said aliphatic heterocyclic moiety is selected from piperidinyl, morpholinyl, thiazolidinyl, and imidazolidinyl; an amino group optionally substituted with 1 to 2 groups independently selected from the group consisting of an alkyl group, a pyridyl group, an alkoxycarbonyl group, an alkylsulfonyl group, and an aminosulfonyl group; a carbamoyl group optionally substituted with 1 to 2 alkyl groups; and a sulfonyl group optionally substituted with a group selected from the group consisting of a pyrrolidinyl group optionally substituted with a hydroxy group and an amino group optionally substituted with 1 to 2 alkyl groups, (2) a cycloalkyl group, (3) a pyridyl group optionally substituted with an alkyl group, (4) a piperidinyl group optionally substituted with 1 to 2 groups independently selected from the group consisting of an alkyl group optionally substituted with 1 to 2 groups independently selected from the group consisting of a halogen atom, a hydroxy group, and a cyano group, and an alkanoyl group, or (5) an alkanoyl group optionally substituted with a tetrahydroisoquinolyl group;\n R 2  represents a hydrogen atom, a halogen atom, an alkyl group, a haloalkyl group, or an alkoxy group; \n Ring B represents a phenyl group, a cycloalkyl group, or a pyridyl group; \n R 4  represents \n (1) an alkyl group, (2) a cycloalkyl group optionally substituted with a carboxyl group, (3) a pyridyl group optionally substituted with an oxadiazolyl group optionally substituted with an oxo group, (4) an aliphatic heterocyclic group optionally substituted with 1 to 2 groups independently selected from the group consisting of a hydroxy group; a halogen atom; an oxo group; a cyano group; an alkyl group; a heteroaryl group optionally substituted with a group selected from the group consisting of a hydroxy group and an oxo group, wherein said heteroaryl moiety is selected from oxazolyl, oxadiazolyl, and tetrazolyl; a carboxyl group; an alkoxycarbonyl group; a carbamoyl group optionally substituted with 1 to 2 alkyl groups; an alkylsulfonyl group; an alkylsulfonylamino group; an alkylsulfonylaminocarbonyl group; and an aminosulfonylaminocarbonyl group optionally substituted with 1 to 2 alkyl groups, wherein said aliphatic heterocyclic moiety is selected from piperidinyl, piperazinyl, morpholinyl, and thiomorpholinyl, or (5) an amino group optionally substituted with 1 to 2 groups independently selected from the group consisting of an alkyl group optionally substituted with a carboxyl group; and\n R 1  and R 6  represent each a group independently selected from the group consisting of a hydrogen atom, a halogen atom, an alkyl group, a haloalkyl group, and a cycloalkyl group, \n or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 42.0
- Percentile: 93.0
- Lexical Diversity: 2.03846
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15313407', '15305587', '13154144', '12919973', '14891845']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7713939892293851
- 35 USC 102 Novelty (BERT): 0.5611239202582985
- Combined Prediction Score: 0.7503669823322764
- Mean Citation Score: 313.940092
- Max Citation Score: 427.80472
- Similarity Product: 353.6558484548569

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test